Last checked at 18 Sep 2020 16:48
18 September 2020
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or "the Group")
Grant of Options
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that the Company has granted a total of 1,809,695 options to subscribe for new ordinary shares in the Company under the SkinBioTherapeutics Share Option Program to Professor Catherine O'Neill, Chief Scientific Officer and Stuart Ashman, CEO both PDMRs of the Company on 3 March and 8 April 2020 respectively (the "Options"). Following an internal review of announcements it was noted that no notification had been made at the time of the relevant grants in accordance with article 19(3) of the Market Abuse Regulation and this announcement corrects this omission.
The Options for Professor O'Neill have vested with immediate effect, are exercisable at a price of 9.5p per share and will expire on 3 March 2030.
The Options for Mr Ashman can be exercised no earlier than 24 months from the date of grant and are subject to achieving performance milestones set by the Company's board which are aligned to growth in shareholder value and commercialisation of the Company's technology. The Options are exercisable at a price of 9p per share and will expire on 8 April 2030.
The following options have been granted to Directors and PDMRs:
| Director | Number of options granted
| Total number of options |
| Catherine O'Neill
| 512,334 | 4,404,416 |
| Stuart John Ashman
| 1,297,361 | 5,189,444 |
SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO | Tel: +44 (0) 161 468 2760 |
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales) | Tel: +44 (0) 20 7397 8900 |
Instinctif Partners Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis | Tel: +44 (0) 20 7457 2020 SkinBio@instinctif.com |
The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Professor Catherine O'Neill | |||||
2 | Reason for notification | Grant of share options | |||||
a. | Position/Status | Chief Scientific Officer | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics Plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Share options for ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
9.5p | 512,334 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 3rd March 2020 | |||||
f. | Place of the transaction | Off market | |||||
| |||||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stuart John Ashman | |||||
2 | Reason for notification | Grant of share options | |||||
a. | Position/Status | Chief Executive Officer | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics Plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Share options for ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
9.0p | 1,297,361 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 8th April 2020 | |||||
f. | Place of the transaction | Off market | |||||